Mesa Laboratories earnings date
Mesa Laboratories (MLI) Q2 2027 Earnings Report
DE:MLI Q2 2027 EPS Results
- Actual EPS
- EUR 1.88
- Consensus EPS
- EUR 2.07
- Beat/Miss
- Missed by -EUR 0.19
- One Year Ago EPS
- EUR 2.49
DE:MLI Q2 2027 Revenue Results
- Actual Revenue
- EUR 56.35M
- Expected Revenue
- EUR 56.22M
- Beat/Miss
- Beat by +EUR 122.93K
- YoY Revenue Growth
- +2.63%
Earnings Announcement Details
- Quarter
- Q2 2027
- Date
- 11/09/2026
- Time
- After Close
- Conference Call
- Monday, November 9, 2026
Mesa Laboratories's next earnings date is estimated for February 8, 2027, based on past reporting schedules.
Q2 2027 Earnings Call Audio
Q2 2027 Earnings Slide Deck
Q2 2027 Earnings Call Summary
The call was predominantly positive, with accelerating organic growth excluding clinical genomics, strong adjusted EBITDA and earnings growth, improved cash generation, debt reduction, lower leverage, and the initiation of fiscal 2027 guidance. The main challenges were the unresolved reliability issue in one sterilization product line, the 8.2% biopharmaceutical development revenue decline, the 8.8% clinical genomics revenue decline and planned revenue reset, margin pressure in Calibration Solutions and clinical genomics, and upcoming restructuring charges. Management characterized the biopharmaceutical development decline as timing- and export-control-related rather than demand-related and described most of the sterilization fix as being in place.
For fiscal 27, Mesa guides to revenues of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million, representing adjusted EBITDA growing about 5% to 8% on revenues up about 0% to 2%, compared with adjusted EBITDA of about $63 million in 2026; the guidance includes the savings plan and its reinvestment and lower clinical genomics revenue, and excludes restructuring charges, which are expected to total pretax charges of $2.6 million to $3.4 million and related cash costs of approximately $2.9 million to 3.7 million. Third quarter revenue is expected to be about flat compared with last year, mainly because clinical genomics revenues stepped down, while outside clinical genomics the businesses are expected to keep growing; Mesa also expects to keep strengthening the balance sheet towards 1.5 to 1.75 turns of net leverage by the end of the fiscal year.
- Organic Revenue Growth AcceleratedOrganic revenues grew 2.6% in the second quarter, up from 1% in the first quarter. Excluding clinical genomics, revenues grew about 5% in the quarter and about 3% in the first half. Sterilization and disinfection control grew in the mid teens organically, while Calibration Solutions grew in the low single digits.
- Sterilization and Disinfection Control Delivered Strong GrowthSterilization and disinfection control grew 14.6% organically in the second quarter, about 5% in the first half, and 8.5% over the trailing 12 months to $104 million, its highest trailing-12-month revenue in the franchise's history. Past-due backlog remained roughly steady at a substantially lower level than a year ago, and customer demand continued.
- Manufacturing Improvements and FDA Inspection ResultManufacturing issues behind delivery delays were resolved on most product lines, allowing shipments to be made on schedules customers can plan around. The FDA inspected the Bozeman facility in September and issued no observations.
- Calibration Solutions Continued Organic GrowthCalibration Solutions grew about 3.5% organically in the quarter, following nearly 11% growth a year ago. The company is adding business development capacity to expand the geographic reach of this business.
- Gross Profit and Operating Income ImprovedGross profit was $39.9 million, or 64% of revenues, up 250 basis points from 61.5% a year ago. GAAP operating income increased 77.6% to $8.4 million.
- Adjusted EBITDA and Earnings IncreasedAdjusted EBITDA increased 21.1% to $17.3 million, or 27.8% of revenues, compared with 23.5% a year ago. Net income increased 75% to $4.3 million, or $0.75 per diluted share, compared with $0.45 a year ago. First-half adjusted EBITDA grew 20.9% on revenue growth of about 1.8%.
- Trailing-Twelve-Month EBITDA Reached $68.6 MillionTrailing-12-month adjusted EBITDA was $68.6 million, or 27.3% of revenues, compared with $53.5 million a year ago.
- Savings Plan and Targeted ReinvestmentThe savings plan is expected to reduce annualized operating costs by approximately $9.3 million. Approximately $4.3 million of those savings will be reinvested primarily in commercial capacity, business development in Calibration Solutions, commercial resources in Asia, and key corporate positions, resulting in expected net annualized cost reduction of approximately $5 million.
- Clinical Genomics Customer RenewalsThe three largest clinical genomics customers each renewed for terms of 2 to 3.5 years, with the longest renewal lasting 3.5 years. These customers use the MassArray at scale and represent closer to 25% of the clinical genomics business.
- Balance Sheet StrengtheningThe company repaid $20.1 million of debt in the first half, including $11.4 million in the second quarter. Net leverage declined to 1.75 times from 1.85 times at the end of June, within the targeted 1.5 to 1.75 times range. The company ended the quarter with $22.3 million of cash and $57.8 million available under its revolver, compared with a covenant maximum net leverage ratio of 3.5 times.
- Strong Operating Cash FlowFirst-half operating cash flow was $18.8 million, up $8.7 million, driven by higher operating income and strong first-quarter collections. Capital expenditures were $900 thousand. Since quarter end, the company repaid an additional $5 million of revolver borrowing.
- Share Repurchase AuthorizationThe board authorized a share repurchase program of up to $40 million through December 31, 2028, to be used opportunistically and with discipline while the company continues to reduce debt.
- Fiscal 2027 Guidance InitiatedThe company initiated fiscal 2027 guidance for revenue of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million. Compared with adjusted EBITDA of about $63 million in fiscal 2026, the guidance represents adjusted EBITDA growth of about 5% to 8% on revenue growth of about 0% to 2%. Management expects adjusted EBITDA to grow faster than revenues for the full year.
- Quality Control Businesses Generated Higher Gross ProfitIn the first half of fiscal 2027, quality control businesses generated $77.2 million of revenue and combined gross profit of $51.3 million, or 66.4% of revenues. Life sciences tools businesses generated $45.3 million of revenue and combined gross profit of $27.6 million, or 61% of revenues.
- Gyrolab Next-Generation Platform Remains on TrackThe next-generation Gyrolab platform remains planned for launch in fiscal 2028, and the company said the commercial rebuild around the biopharmaceutical development general manager is continuing.
- China Growth Across Several BusinessesThe China market grew 20% in the quarter, driven primarily by robust businesses in China across the company, especially sterilization and disinfection control and portions of biopharmaceutical development. Clinical genomics declined slightly in China.
- Leadership AdditionSanket Shah joined Mesa on November 2 as General Counsel, strengthening the leadership team.
- Planned Distributor and Quality Control AcquisitionsThe company expects to bring a small number of distributors in house to gain direct customer access and service relationships, followed by small tuck-in acquisitions in quality control businesses when its earnings record and balance sheet support that activity. Management said quality control markets offer more tuck-in availability and less full valuations than life sciences tools markets.
DE:MLI Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 08, 2027 | 2027 (Q3) | 2.73- | 2.78 | ― | ― |
| Nov 09, 2026 | 2027 (Q2) | 2.071.88 | 2.49 | -24.22% (-0.60) | |
| Aug 10, 2026 | 2027 (Q1) | 2.372.42 | 2.1 | 15.52% (+0.33) | |
| May 27, 2026 | 2026 (Q4) | 1.882.98 | 2.03 | 46.67% (+0.95) | |
| Feb 03, 2026 | 2026 (Q3) | 1.752.78 | 2.46 | 12.87% (+0.32) | |
| Nov 06, 2025 | 2026 (Q2) | 2.082.49 | 2.37 | 4.96% (+0.12) | |
| Aug 05, 2025 | 2026 (Q1) | 2.052.10 | 2.56 | -18.02% (-0.46) | |
| May 28, 2025 | 2025 (Q4) | 2.072.03 | 2.5 | -18.77% (-0.47) | |
| Feb 04, 2025 | 2025 (Q3) | 1.562.46 | 1.83 | 34.65% (+0.63) | |
| Nov 07, 2024 | 2025 (Q2) | 1.712.37 | 1.73 | 37.17% (+0.64) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
